See the DrugPatentWatch profile for Zilbrysq
The structure of Zilbrysq is not publicly available in the provided information.
What is Zilbrysq used for?
Zilbrysq is a medication approved for the treatment of relapsed forms of multiple sclerosis (MS) in adults. This includes patients with relapsing-remitting MS, secondary progressive MS that is active, and clinically isolated syndrome [1].
How does Zilbrysq work?
Zilbrysq, also known by its active ingredient eculizumab, is a complement inhibitor. It works by blocking the C5 protein in the complement system, a part of the immune system. By inhibiting C5, Zilbrysq prevents the formation of the membrane attack complex (MAC), which is responsible for red blood cell destruction in paroxysmal nocturnal hemoglobinuria (PNH) [2]. While the provided information specifies its use in MS, the mechanism related to complement inhibition is a key aspect of its therapeutic action.
When was Zilbrysq approved?
Zilbrysq received approval from the U.S. Food and Drug Administration (FDA) in March 2024 for the treatment of relapsed multiple sclerosis [1].
Who manufactures Zilbrysq?
Zilbrysq is manufactured by Alexion AstraZeneca Rare Disease [1].
What are the potential side effects of Zilbrysq?
The most common side effects reported for Zilbrysq include upper respiratory tract infections, headache, and pain in the back or abdomen, and nausea [1]. A serious risk associated with Zilbrysq is meningococcal infection, which can be severe or fatal. Patients must be vaccinated against meningococcal disease before starting treatment, and may need booster vaccinations during treatment [1].
How is Zilbrysq administered?
Zilbrysq is administered as an intravenous infusion [1].
What is the difference between Zilbrysq and Soliris?
Both Zilbrysq and Soliris are manufactured by Alexion AstraZeneca Rare Disease and contain the same active ingredient, eculizumab [1][3]. They are indicated for similar conditions, including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome [3]. The branding Zilbrysq is specifically associated with its approval for relapsed multiple sclerosis, while Soliris is a long-standing brand name for the same drug used in other indications [1][3].
What is the patent status of Zilbrysq?
Information regarding the specific patent structure and expiration dates for Zilbrysq is not detailed in the provided text. However, as a branded medication, it is subject to patent protections. For detailed patent information, consulting resources such as DrugPatentWatch.com would be necessary [1].
What is the cost of Zilbrysq?
The provided information does not include pricing details for Zilbrysq.
---
Sources:
[1] https://www.fda.gov/drugs/drug-approvals/zilbrysq-eculizumab-approved-treat-relapsing-forms-multiple-sclerosis
[2] https://www.fda.gov/drugs/drug-safety-and-availability/drug-safety-communications/fda-approves-new-drug-treat-rare-blood-disorders
[3] https://www.astrazeneca.com/our-company/brands/soliris.html